Company / Cash & Equivalents
Editas Medicine, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$146.6M
FY2025
5-year range
$131.5M / $203.5M
FY2021-FY2025
Trend
+11.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $132M in FY2024 to $238M in FY2019.
Based on SEC 10-K filings.
$147M in FY2025 with a 5-year CAGR of +1.0%.
Improved from $142M to $147M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +1.2%
- 5-Year CAGR
- +1.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +1.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 11.5% year-over-year.
- Peak cash & equivalents was recorded in FY2019.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $146.6M | +11.5% |
| FY2024 | $131.5M | -7.1% |
| FY2023 | $141.5M | +0.0% |
| FY2022 | $141.5M | -30.5% |
| FY2021 | $203.5M | +45.7% |
| FY2020 | $139.7M | -41.4% |
| FY2019 | $238.2M | +62.4% |
| FY2018 | $146.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026